Unicycive Therapeutics, Inc. engages in the development of treatment for kidney diseases. The company is headquartered in Los Altos, California and currently employs 22 full-time employees. The company went IPO on 2021-06-17. The firm's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.
Follow-Up Questions
Unicycive Therapeutics Inc 'in CEO'su kimdir?
Dr. Shalabh Gupta 2016 'den beri şirketle birlikte olan Unicycive Therapeutics Inc 'in Chairman of the Board 'ıdır.
UNCY hissesinin fiyat performansı nasıl?
UNCY 'in mevcut fiyatı $4.95 'dir, son işlem günde 5.09% increased etti.
Unicycive Therapeutics Inc için ana iş temaları veya sektörler nelerdir?
Unicycive Therapeutics Inc Biotechnology endüstrisine ait ve sektör Health Care 'dir
Wall Street analistlerine göre, 10 analist Unicycive Therapeutics Inc için analist derecelendirmeleri gerçekleştirdi, bunlar 3 güçlü al, 10 al, 1 tut, 0 sat ve 3 güçlü sat içermektedir
